Abstract
a peer-reviewed, open access online international journal which publishes original research papers. The journal welcomes submission from scholars and experts for possible publication from all over the world. The scope of the journal includes: Pharmaceutical research, chemistry and biochemistry of naturally occurring compounds, biological evaluation of crude extracts, ethnomedicine, traditional and complementary medicine, ethnopharmacology, biomedical research, Biotechnology, Evaluation of natural substances of land and sea and of plants, microbes and animals, pharmacognosy, bioavailability, clinical, pharmacological, toxicological studies and pharmacokinetics of phytochemicals, Isolation and characterization of compounds, structure elucidation, synthesis and experimental biosynthesis of natural Product as well as developments of methods in these areas are welcomed in the journal.
Highlights
Diabetic kidney disease (DKD) is increasing in prevalence and severity worldwide.[1]
According to the ninth edition of the Global Diabetes Overview released by the International Diabetes Federation, the global prevalence of diabetes will increase from 463 million in 2019 to 700 million in 2045.2,3 Approximately 10–40% of patients with type 2 diabetes (T2D) will develop DKD,[4] and 30–40% of these patients will progress to renal failure.[5,6]
Tang Shen 2 Hao Fang formulation The TS2HF components used in this study met the standards of the Vietnamese pharmacopeia V 2020 and included the following: Astragalus mongholicus Bunge 30 g, Euonymus alatus (Thunb.) Sieb 15 g, Pheretima 10 g, Pseudostellaria heterophylla (Miq.) Pax ex Pax et Hoffm 15 g, Rheum palmatum L.6 g, Salvia miltiorrhiza Bunge 15 g, cicada slough 6 g, and Herba lycopi 15 g
Summary
Diabetic kidney disease (DKD) is increasing in prevalence and severity worldwide.[1] According to the ninth edition of the Global Diabetes Overview released by the International Diabetes Federation, the global prevalence of diabetes will increase from 463 million in 2019 to 700 million in 2045.2,3 Approximately 10–40% of patients with type 2 diabetes (T2D) will develop DKD,[4] and 30–40% of these patients will progress to renal failure.[5,6] Treatment for DKD includes controlling blood pressure and blood glucose, by using inhibitors of the renin-angiotensin-aldehyde ketone system This is the primary treatment for DKD, it is not effective in delaying its progression,[7,8] and approximately 20% of patients with diabetes will develop end-stage renal disease.[9] Diabetic nephropathy (DN) is a chronic disease characterized by a reduced glomerular filtration rate.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
